Clinical trials
Recurrent Ovarian Cancer clinical trials
Below are recruiting recurrent ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 227 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06420973RecruitingPhase 2
Testing RC48 for ovarian cancer returning after platinum treatment
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06430541RecruitingPhase 1
Psilocybin therapy for fear of cancer recurrence
This trial tests if psilocybin-assisted therapy can help reduce the intense worry that cancer might come back. It is for people who have finished their main treatments for early-stage breast cancer or advanced ovarian cancer.
Aurora, ColoradoAges 21 years+ - NCT06434610RecruitingPhase 2
Study of B013 plus paclitaxel for ovarian cancer
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
BeijingAges 18–75 - NCT06152731RecruitingPhase 2
HRD testing for advanced ovarian cancer
This study collects tumor samples from people newly diagnosed with advanced ovarian cancer to test for HRD, a genetic feature that may help doctors predict which treatments work best. The goal is to see if HRD testing can guide future treatment decisions for patients like you.
AmiensAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06386887Recruiting
Fasting During Chemotherapy for Ovarian Cancer
This trial tests whether adding periods of fasting to standard chemotherapy before surgery helps people with advanced ovarian cancer. It is for those receiving platinum-based chemo for the first time or after recurrence.
Cleveland, OhioAges 18 years+ - NCT06366490RecruitingPhase 1
Personalized vaccine for recurrent ovarian cancer
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85 - NCT06305299RecruitingPhase 1
CAR-T cell therapy for ovarian cancer
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
Chapel Hill, North CarolinaAges 18 years+ - NCT06295965Recruiting
Blood changes and cancer therapy study
This study looks at why some people develop blood disorders after cancer treatment. It monitors changes in blood cells to better predict and prevent these problems.
Seattle, WashingtonAges Any age - NCT06127446Recruiting
Genetic Changes in Ovarian Cancer in Taiwan
This trial is creating a detailed registry of genetic changes found in ovarian tumors in Taiwan. It aims to better understand the disease by collecting tumor tissue and blood samples from patients with high-grade serous or clear cell ovarian, fallopian tube, or peritoneal cancer.
Kaohsiung CityAges 18 years+ - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT06072781RecruitingPhase 3
Study of Avutometinib + Defactinib for recurrent low-grade ovarian cancer
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
Phoenix, ArizonaAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT05773859RecruitingPhase 1/Phase 2
Vaccination before surgery to treat advanced ovarian cancer
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
Nijmegen, GelderlandAges 18 years+ - NCT05990192RecruitingPhase 2
SBRT with or without niraparib for ovarian cancer after PARP inhibitor treatment
This trial tests a new treatment approach for people with ovarian cancer that has started to progress in a few spots (up to 3) after taking a PARP inhibitor. It combines targeted radiation (SBRT) to those spots, followed by another PARP inhibitor (niraparib), to see if this can control the cancer further.
Leeds, LeedsAges 18 years+ - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT05942300RecruitingPhase 1
CPI-0209 plus platinum chemo for recurring ovarian cancer
This Phase 1 trial tests CPI-0209 combined with the standard platinum chemotherapy approach in people whose ovarian (or related) cancer has returned after prior platinum treatment. The goal is to find a safe dose and see whether this combination can help keep the cancer under control.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05804370RecruitingPhase 3
Gleolan to help surgeons find ovarian cancer during surgery
This Phase 3 study tests whether Gleolan (a medicine given before surgery) helps doctors better see ovarian, fallopian tube, or peritoneal cancer during an operation. It may help improve how well surgeons can remove visible tumor tissue during planned surgery.
Phoenix, ArizonaAges 18 years+ - NCT05739981RecruitingPhase 1/Phase 2
Immunotherapy plus chemo for newly diagnosed advanced ovarian cancer
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
Baltimore, MarylandAges 18 years+ - NCT05610735RecruitingPhase 1/Phase 2
Study drug combination for ovarian cancer after platinum stops working
This Phase 1/2 trial tests a combination treatment for recurrent ovarian, fallopian tube, or primary peritoneal cancer when platinum chemotherapy stops working. If you qualify, the study aims to control the cancer and see how well the treatment is tolerated.
Louisville, KentuckyAges 18 years+ - NCT05636111RecruitingPhase 1
Study drug lurbinectedin with weekly paclitaxel and bevacizumab
This Phase 1b trial tests how well a new cancer drug (lurbinectedin) works together with weekly paclitaxel and bevacizumab in ovarian, fallopian tube, or peritoneal cancer that has returned or worsened after platinum chemotherapy. It’s designed to find the best way to use these medicines and check for early signs of benefit and safety.
Houston, TexasAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent ovarian cancer?
- Yes. Clin2 currently lists 227 recruiting recurrent ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.